Development of amphotericin B-loaded fibroin nanoparticles: a novel approach for topical ocular application
Source abstract
Abstract
Fungal keratitis (FK), the major cause of ocular morbidity worldwide, is commonly treated with the amphotericin B (AmB) eye drops extemporaneously prepared from marketed parenteral formulations. However, these in-house prepared AmB eye drops have the drawbacks of poor ocular bioavailability and eye irritation. The aim of this study was to develop AmB-loaded fibroin nanoparticles (AmB-FNPs), in combination with the polymer PEG 400, as ready-to-use eye drops for FK. The AmB-FNPs were prepared by desolvation method. All AmB-FNPs exhibited homogeneous spherical particles with a mean size of ~ 270 nm, the zeta potential of ~ − 17 mV, and an entrapment efficiency of ~ 65%. Using X-ray diffraction and UV analysis, AmB demonstrated amorphous molecular dispersion and monomeric form when entrapped in the FNPs. Interestingly, in dissolution studies, although AmB-FNPs showed no detectable drug release in sink condition, they still possessed good antifungal activity against Candida albicans. Potentially, AmB-FNPs showed less cytotoxicity in human corneal epithelial cell line compared to the marketed AmB deoxycholate.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Ocular Surface and Contact Lens · Essential Oils and Antimicrobial Activity
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. Gallis HA, Drew RH, Pickard WW (1990) Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12(2):308–32910.1093/clinids/12.2.308 ↗
2. Tuli SS (2011) Fungal keratitis. Clin Ophthalmol 5:275–27910.2147/OPTH.S10819 ↗
3. Thomas PA, Kaliamurthy J (2013) Mycotic keratitis: epidemiology, diagnosis and management. Clin Microbiol Infect 19(3):210–22010.1111/1469-0691.12126 ↗
4. Chhonker YS, Prasad YD, Chandasana H, Vishvkarma A, Mitra K, Shukla PK, Bhatta RS (2015) Amphotericin-B entrapped lecithin/chitosan nanoparticles for prolonged ocular application. Int J Biol Macromol 72:1451–145810.1016/j.ijbiomac.2014.10.014 ↗
5. Morand K, Bartoletti AC, Bochot A, Barratt G, Brandely ML, Chast F (2007) Liposomal amphotericin B eye drops to treat fungal keratitis: physico-chemical and formulation stability. Int J Pharm 344(1–2):150–15310.1016/j.ijpharm.2007.04.028 ↗
6. Fu T, Yi J, Lv S, Zhang B (2017) Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. J Liposome Res 27(3):228–23310.1080/08982104.2016.1224899 ↗
7. Suresh PK, Sah AK (2014) Nanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions. Expert Opin Drug Deliv 11(11):1747–176810.1517/17425247.2014.938045 ↗
8. Baranowski Przemysław, Karolewicz Bożena, Gajda Maciej, Pluta J (2014) Ophthalmic drug dosage forms: characterisation and research methods. Sci World J 2014:14
9. Das S, Suresh PK (2011) Nanosuspension: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine 7(2):242–24710.1016/j.nano.2010.07.003 ↗
10. Gratieri T, Gelfuso GM, Lopez RFV, Souto EB (2010) Current efforts and the potential of nanomedicine in treating fungal keratitis. Expert Rev Ophthalmol 5(3):365–38410.1586/eop.10.19 ↗
11. Sharma A, Taniguchi J (2017) Review: emerging strategies for antimicrobial drug delivery to the ocular surface: Implications for infectious keratitis. Ocul Surf 15(4):670–67910.1016/j.jtos.2017.06.001 ↗
12. Zhou W, Wang Y, Jian J, Song S (2013) Self-aggregated nanoparticles based on amphiphilic poly(lactic acid)-grafted-chitosan copolymer for ocular delivery of amphotericin B. Int J Nanomed 8:3715–3728
13. Soliman GM (2017) Nanoparticles as safe and effective delivery systems of antifungal agents: achievements and challenges. Int J Pharm 523(1):15–3210.1016/j.ijpharm.2017.03.019 ↗
14. Chaiyasan W, Srinivas SP, Tiyaboonchai W (2015) Crosslinked chitosan-dextran sulfate nanoparticle for improved topical ocular drug delivery. Mol Vis 21:1224–1234
15. Chen Y-C, Su C-Y, Jhan H-J, Ho H-O, Sheu M-T (2015) Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int J Nanomed 10:7265–7274
16. Das S, Suresh PK, Desmukh R (2010) Design of Eudragit RL 100 nanoparticles by nanoprecipitation method for ocular drug delivery. Nanomedicine 6(2):318–32310.1016/j.nano.2009.09.002 ↗
17. Xu Z, Shi L, Yang M, Zhu L (2019) Preparation and biomedical applications of silk fibroin-nanoparticles composites with enhanced properties—a review. Mater Sci Eng C 95:302–31110.1016/j.msec.2018.11.010 ↗
18. Lozano-Perez AA, Rodriguez-Nogales A, Ortiz-Cullera V, Algieri F, Garrido-Mesa J, Zorrilla P, Rodriguez-Cabezas ME, Garrido-Mesa N et al (2014) Silk fibroin nanoparticles constitute a vector for controlled release of resveratrol in an experimental model of inflammatory bowel disease in rats. Int J Nanomed 9:4507–4520
19. Pham DT, Saelim N, Tiyaboonchai W (2018) Crosslinked fibroin nanoparticles using EDC or PEI for drug delivery: physicochemical properties, crystallinity and structure. J Mater Sci 53(20):14087–14103. https://doi.org/10.1007/s10853-018-2635-310.1007/s10853-018-2635-3 ↗
20. Sharma S, Bano S, Ghosh AS, Mandal M, Kim H-W, Dey T, Kundu SC (2016) Silk fibroin nanoparticles support in vitro sustained antibiotic release and osteogenesis on titanium surface. Nanomed (NBM) 12(5):1193–120410.1016/j.nano.2015.12.385 ↗
21. Zhang YQ, Ma Y, Xia YY, Shen WD, Mao JP, Zha XM, Shirai K, Kiguchi K (2006) Synthesis of silk fibroin-insulin bioconjugates and their characterization and activities in vivo. J Biomed Mater Res B Appl Biomater 79(2):275–28310.1002/jbm.b.30539 ↗
22. Pham DT, Saelim N, Tiyaboonchai W (2018) Design of experiments model for the optimization of silk fibroin based nanoparticles. Int J Appl Pharm 10(5):195–20110.22159/ijap.2018v10i5.28139 ↗
23. Pham DT, Saelim N, Tiyaboonchai W (2019) Alpha mangostin loaded crosslinked silk fibroin-based nanoparticles for cancer chemotherapy. Colloids Surf B Biointerfaces 181:705–71310.1016/j.colsurfb.2019.06.011 ↗
24. Zhao Z, Li Y, Xie MB (2015) Silk fibroin-based nanoparticles for drug delivery. Int J Mol Sci 16(3):4880–490310.3390/ijms16034880 ↗
25. Nimtrakul Pataranapa, Tiyaboonchai Waree, Lamlertthon S (2019) Amphotericin B loaded nanostructured lipid carriers for parenteral delivery: characterization, antifungal and in vitro toxicity assessment. Curr Drug Deliv 16(7):645–65310.2174/1567201816666190729145223 ↗
26. Wong SSW, Kao RYT, Yuen KY, Wang Y, Yang D, Samaranayake LP, Seneviratne CJ (2014) In vitro and in vivo activity of a novel antifungal small molecule against candida infections. PLoS ONE 9(1):e8583610.1371/journal.pone.0085836 ↗
27. Rodriguez-Tudela JL, Cuenca-Estrella M, Diaz-Guerra TM, Mellado E (2001) Standardization of antifungal susceptibility variables for a semiautomated methodology. J Clin Microbiol 39(7):2513–251710.1128/JCM.39.7.2513-2517.2001 ↗
28. Takahashi Y, Koike M, Honda H, Ito Y, Sakaguchi H, Suzuki H, Nishiyama N (2008) Development of the short time exposure (STE) test: an in vitro eye irritation test using SIRC cells. Toxicol In Vitro 22(3):760–77010.1016/j.tiv.2007.11.018 ↗
29. Chanburee S, Tiyaboonchai W (2017) Mucoadhesive nanostructured lipid carriers (NLCs) as potential carriers for improving oral delivery of curcumin. Drug Dev Ind Pharm 43(3):432–44010.1080/03639045.2016.1257020 ↗
30. Niamprem P, Srinivas SP, Tiyaboonchai W (2018) Development and characterization of indomethacin-loaded mucoadhesive nanostructured lipid carriers for topical ocular delivery. Int J Appl Pharm 10(2):91–9610.22159/ijap.2018v10i2.24738 ↗
31. Schuerer N, Stein E, Inic-Kanada A, Pucher M, Hohenadl C, Bintner N, Ghasemian E, Montanaro J et al (2017) Implications for ophthalmic formulations: ocular buffers show varied cytotoxic impact on human corneal-limbal and human conjunctival epithelial cells. Cornea 36(6):712–71810.1097/ICO.0000000000001199 ↗
32. Barwicz J, Christian S, Gruda I (1992) Effects of the aggregation state of amphotericin B on its toxicity to mice. Antimicrob Agents Chemother 36(10):2310–231510.1128/AAC.36.10.2310 ↗
33. Churchill DN, Seely J (1977) Nephrotoxicity associated with combined gentamicin-amphotericin B therapy. Nephron 19(3):176–18110.1159/000180883 ↗
34. Adams ML, Kwon GS (2003) Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block–poly(N-hexyl-l-aspartamide)-acyl conjugate micelles: effects of acyl chain length. J Control Release 87(1):23–3210.1016/S0168-3659(02)00347-4 ↗
35. Barwicz J, Tancrède P (1997) The effect of aggregation state of amphotericin-B on its interactions with cholesterol- or ergosterol-containing phosphatidylcholine monolayers. Chem Phys Lipids 85(2):145–15510.1016/S0009-3084(96)02652-7 ↗
36. Zia Q, Khan AA, Swaleha Z, Owais M (2015) Self-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans. Int J Nanomed 10:1769–1790
37. Lemke A, Kiderlen AF, Kayser O (2005) Amphotericin B. Appl Microbiol Biotechnol 68(2):151–16210.1007/s00253-005-1955-9 ↗
38. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S (2008) Amphotericin B formulations and drug targeting. J Pharm Sci 97(7):2405–242510.1002/jps.21179 ↗
39. Merisko-Liversidge E, Liversidge GG, Cooper ER (2003) Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18(2):113–12010.1016/S0928-0987(02)00251-8 ↗
40. Dizaj SM, Vazifehasl Z, Salatin S, Adibkia K, Javadzadeh Y (2015) Nanosizing of drugs: effect on dissolution rate. Res Pharm Sci 10(2):95–108
41. Tiyaboonchai W, Limpeanchob N (2007) Formulation and characterization of amphotericin B–chitosan–dextran sulfate nanoparticles. Int J Pharm 329(1):142–14910.1016/j.ijpharm.2006.08.013 ↗
42. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ (2002) Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 46:834–84010.1128/AAC.46.3.834-840.2002 ↗
43. Hartsel SC, Bauer E, Kwong EH, Wasan KM (2001) The effect of serum albumin on amphotericin B aggregate structure and activity. Pharm Res 18(9):1305–130910.1023/A:1013090011952 ↗
44. Casa DM, Karam TK, Alves Ade C, Zgoda AA, Khalil NM, Mainardes RM (2015) Bovine serum albumin nanoparticles containing amphotericin B: characterization, cytotoxicity and in vitro antifungal evaluation. J Nanosci Nanotechnol 15(12):10183–1018810.1166/jnn.2015.11694 ↗
45. Bang JY, Song CE, Kim C, Park WD, Cho KR, Kim PI, Lee SR, Chung WT et al (2008) Cytotoxicity of amphotericin B-incorporated polymeric micelles composed of poly(dl-lactide-co-glycolide)/dextran graft copolymer. Arch Pharm Res 31(11):1463–146910.1007/s12272-001-2131-0 ↗